TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable patients \>= 18 years of age referred for cardiac catheterization for evaluation of cardiac symptoms ( angina, fatigue, or shortness of breath)~* At least 1 indeterminate stenosis (20-80%), fractional flow reserve (FFR) \>=0.8 and PCI deferred~Exclusion Criteria:~* Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) during the index procedure or anticipated within the next month~* acute coronary syndrome or cardiogenic shock~* use of strong inhibitors of CTP3A (i.e. ketoconazole, itraconazole, clarithromycin,nefazodone, nelfinavir, ritonavir, indinavir and saquinavir)~* use of inducers of CYP3A (i.e. rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort)~* liver cirrhosis~* sever renal insufficience (i.e. creatinine clearance \< 30mL/min/1.73 m2)~* QTc \> 500 milliseconds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: ACTIVE_COMPARATOR): Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks
- Sugar pill (Type: PLACEBO_COMPARATOR): Sugar pill that looks like the drug ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly started on Home parenteral Nutrition and anticipated duration \>3 months.~* Not previously on Home Parenteral Nutrition.~* Providing consent.~* Patients with non-medicare insurance.~* Patients with medicare insurance and a supplementary insurance.~* Patients with single lumen Hickman® catheters.~* No known alcohol addiction.~Exclusion Criteria:~* Failure to provide consent~* Patients with medicare insurance and no other supplemental private insurance~* Patients with a catheter type other than a single lumen Hickman®~* Patients who are on HPN for less than three months~* Pregnant patients~* Patients who have previous proven addiction and dependence to alcohol.~* Patients lacking capacity to provide consent~* Patients who are not be managed by HPN team at investigator's institution

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ethanol Lock and Normal Saline (Type: EXPERIMENTAL): All patients randomized to the ELT group will receive 3ml of 70% ethanol and saline flush.
- Heparin and Normal Saline (Type: ACTIVE_COMPARATOR): All patients randomized to this group will receive Heparin lock + saline infusion (current standard of care).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: tDCS & Auditory Hallucinations in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18-60~* Primary diagnosis of Diagnostic and Statistical Manual, fifth edition, schizophrenia~* Persistent auditory verbal hallucinations~* Right handed~* Under stable doses of antipsychotic medication for ≥4 weeks~* Normal hearing by self-report and physical exam~* Use of effective method of birth control for women of childbearing capacity~* Capable to provide informed consent. For patients judged to be incapable to provide informed consent the legal guardian of the patient must agree to participation in the study and provide signed informed consent~Exclusion Criteria:~* Current or past history of substance dependence or abuse (excluding nicotine)~* Other current Axis I disorders~* History of seizure, epilepsy in self or first degree relatives, stoke, brain surgery, head injury, intracranial metal implants, known structural brain lesion, devices that may be affected by tDCS (pacemaker, medication pump, cochlear implant, implanted brain stimulator)~* Frequent and persistent migraines~* History of adverse reaction to neurostimulation~* Participation in study of investigational medication within 6 weeks~* Pregnancy~* Women who are breast-feeding~* Current significant laboratory abnormality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Active tDCS (Type: EXPERIMENTAL): active tDCS
- control (Type: SHAM_COMPARATOR): sham (placebo) tDCS condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-75 years of age;~* type 2 diabetes;~* normal hepatic function, or mild or moderate hepatic impairment.~Exclusion Criteria:~* type 1 diabetes, or latent autoimmune diabetes in adults;~* diabetic neuropathy, retinopathy or nephropathy;~* treatment with insulin or PPAR gamma agonist within 6 weeks of screening;~* clinically significant cardiovascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Modafinil in Opioid Induced Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Epworth Sleepiness Scale \> 10~* Etiology of sleepiness is attributed only to opioids~* Patient must have been taking an opioid for more than 2 weeks or have been on a non-escalating dose of opioids for at least 1 week~* Patient must be able to give written informed consent~* Age \>18 years~Exclusion Criteria:~* Hypersensitivity to modafinil~* Mini-Mental Status Exam (MMSE) \< 25/30~* Renal impairment (calculated creatinine clearance \< 40)~* Hepatic dysfunction (total bilirubin \> 1.8, AST \> 75IU/l, ALT \> 100IU/l, prothrombin time \> 40%~* Known history of cardiovascular disease (i.e., left ventricular hypertrophy, ischemic ECG changes, chest pain, arrhythmia, mitral valve prolapse, recent myocardial infarction, unstable angina, uncontrolled hypertension)~* Woman who are pregnant, breast-feeding or on hormonal contraception~* Patients taking tricyclic antidepressants, CNS stimulants, hormonal contraceptives or drugs that are inhibitors or inducers of CYP 3A4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Embolism and PCT. PE-PCT Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* CT diagnosis of pulmonary embolism~* Temperature\> 37.8 ° C~* About affiliated to the social security~* Prior agreement with the patient signing a consent~Exclusion Criteria:~* Pregnant Woman~* Refusal of the patient~* Pulmonary Neoplasia~* Antibiotic ongoing for more than 24 hours at the time of diagnosis of pulmonary embolism~* Cardiogenic shock (hypotension with mean arterial pressure less than 65 bpm)~* Suspicion of infection other than lung associated (associated urinary tract infection, prostatitis, ENT infection, sinusitis ...)~* Patient under guardianship~* Patients unable to give consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clinical group (Type: EXPERIMENTAL): In the first group of patients, the use of antibiotics will be guided by clinical (clinical group).
- PCT group (Type: OTHER): In the second group, the use of antibiotics will be guided by the algorithm (PCT group).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~Participants must meet all of the following criteria in order to be eligible to participate in the study:~* Male or female ≥1 year of age.~* Had an allogeneic hematopoietic cell transplant (HCT) performed ≥21 days and ≤1 year prior to randomization.~* Myeloid engraftment confirmed, defined as an absolute neutrophil count ≥500/mm³ for 3 consecutive laboratory values obtained on different days, and platelet count \>10,000/mm³ at the time of randomization.~* Diagnosed with HC based on the following criteria (all 3 criteria must be met):~  1. Clinical signs and/or symptoms of cystitis.~ 2. Grade ≥3 hematuria, defined as macroscopic hematuria with visible clots.~ 3. Viruria with ≥1 target virus (ie, BKV, JCV, AdV, CMV, EBV, and/or HHV-6).~* At least 1 identified, suitably matched posoleucel (ALVR105) cell line for infusion is available.~Key Exclusion Criteria~Participants who meet any of the following criteria will be excluded from participation in the study:~* Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose \>0.5 mg/kg/day or equivalent).~* Therapy with antithymocyte globulin, alemtuzumab (Campath-1H), or other immunosuppressive T cell-targeted monoclonal antibodies ≤28 days before randomization.~* Evidence of active Grade \>2 acute graft versus host disease (GVHD).~* Uncontrolled or progressive bacterial or fungal infections.~* Uncontrolled or progressive viral infections not targeted by posoleucel (ALVR105).~* Uncontrolled or progressive EBV-associated post-transplant lymphoproliferative disorder.~* Known or presumed pneumonia secondary to any organism that is not considered to be well-controlled by antimicrobial therapy.~* Pregnant or lactating or planning to become pregnant.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
- Posoleucel (ALVR105) (Type: EXPERIMENTAL): Administered as 2-4 milliliter infusion, visually identical to placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. pathologically confirmed untreated NPC patients staged N2-3M0~2. age: 18y - 65y~3. with MRI examinations~4. ECOG≤2~5. with written consent~Exclusion Criteria:~1. without a second cancer~2. pregnancy~3. with other severe diseases(blood,liver ,kidney or heart diseases)~4. could not staged properly~5. without written consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Adjuvant chemotherapy with paclitaxel and nedaplatin (Type: EXPERIMENTAL): Patients will receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
- Observation (Type: NO_INTERVENTION): Patients will be followed up without adjuvant chemotherapy after concurrent chemoradiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Response During Goal Directed Fluid Therapy in the OR

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults ≥18 years booked for an open abdominal procedure~2. American Society of Anaesthesiologists (ASA) Physical Status 1 - 3~3. Expected duration of surgical procedure to be ≥ 2 hours~4. Standard of care monitoring to include cardiac output~Exclusion Criteria:~1. Open chest surgical procedure expected~2. Cardiac arrhythmia such as atrial fibrillation.~3. Right Ventricular Failure~4. Aortic regurgitation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Initial bolus pre-incision (Type: OTHER): Initial pre-incision bolus of 500 cc of fluids with hemodynamic response recorded

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3463251 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females~Exclusion Criteria:~* Diagnosed with Type 1 or Type 2 diabetes~* Women who are of childbearing potential or who are breastfeeding~* Donated blood of more than 500 millilitres (mL) within the previous 3 months of study screening~* Have used any tobacco product within 3 months of Day -1, or are unwilling to refrain from the use of tobacco during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LY3463251 Single dose (Type: EXPERIMENTAL): Single dose of LY3463251 administered subcutaneously (SC)
- Placebo Single dose (Type: PLACEBO_COMPARATOR): Single dose of placebo administered SC
- LY3463251 Multiple Dose (Type: EXPERIMENTAL): Multiple doses of LY3463251 administered SC
- Placebo Multiple Dose (Type: PLACEBO_COMPARATOR): Multiple doses of placebo administered SC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Global Lomitapide Pregnancy Exposure Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant females exposed to lomitapide at any time within 30 days prior to first day of the LMP or during pregnancy.~Exclusion Criteria:~* Patients who are unable or unwilling to provide written informed consent or assent are not eligible to participate in the PER.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>65 years old~* Male and Female~* Living in the community~Exclusion Criteria:~* Suffer from unstable conditions, for example, unstable heart disease, severe heart failure, severe renal failure, cirrhosis, blood pressure above 160/100;~* patient who suffer from glaucoma, hyperthyroididsm, epilepsy, patients after stroke, patient with Parkinson's disease, major depression, schizophrenia or receiving neuroleptic drugs;~* patient who suffer from dementia~* patients that recieve treatment in acetylcholinesterase inhibitors or memantine.~* known sensitivity to methylphenidate.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylphenidate (Type: EXPERIMENTAL): On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention. Two hours after taking the drug participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
- Placebo (Type: PLACEBO_COMPARATOR): Participants in the control group will receive placebo. On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of Placebo every day of intervention. Two hours after taking the placebo participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Respiratory Tele Monitoring COVID 19 (TMR COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with COVID 19 pneumonia assessed by PCR and CT scann.~* Patient admited in a dedicated medical ward~* Patient with oxygen supply less or equal to 4 liters per minute.~* Written informed consent~Exclusion Criteria:~* Patient with limitation of care.~* Patient with immediate risk to ICU transfer within the first 12 hours~* Patient with neurological or psychiatric symptoms that interfere with respiratory parameters interpretation.~* Patient with acute or chronic respiratory disease such as COPD, cancer.~* Pregnancy, age \< 18 of vulnerable profile.~* Patient refusal to participate or previously included in a clinical research trial.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Respiratory Monitoring Group (Type: ACTIVE_COMPARATOR): None
- Experimental Respiratory Monitoring Group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For GBS group: Inpatients with acute, progressive weakness and no alternative diagnosis, with onset less than 30 days prior to examination.~* For control group: Hospitalized patients on the inpatient neurology service who are being treated for non-peripheral nerve disorders (e.g. epilepsy, multiple sclerosis, or stroke).~* For all subjects: 18+ years of age~Exclusion Criteria:~- Patients with any history of multifocal motor neuropathy (MMN), prior Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), or hereditary neuropathy (e.g. Charcot-Marie-Tooth)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GBS Patients (Type: EXPERIMENTAL): None
- Controls (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~In this study, included will be patients with corneal neovascularization secondary to various pathologies, including: Pterygium, Corneal chemical burn, S/P corneal transplantation, Herpetic keratitis, atopic keratoconjunctivitis, Chronic retinal detachment, Uveitis, panus secondary to blepharitis, S/P corneal foreign body.~Exclusion Criteria:~1. Patients with a history of retinal vein/artery occlusion or diabetes, currently treated with anti-VEGF or with a history of such treatment 3 months prior to enrollment.~2. Prior treatment for corneal neovascularization with the injection of Avastin/Lucentis.~3. Patients under 18~4. Pregnant women~5. Contra indications for Eylea treatment, including intraocular or periocular infection/inflammation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SC Aflibercept (Type: EXPERIMENTAL): The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues